argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
22 oct 2015 - 07:00
Statutory name
argenx SE
Title
arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders
Comments
- Potential breakthrough therapy for treatment of autoimmune crisis
- Fourth arGEN-X drug candidate entering human trials in 6 years of operations
Date last update: 07 April 2026